News and Trends 26 Oct 2022 ABL and RD-Biotech to partner on cell and gene therapy manufacturing French companies ABL and RD-Biotech have signed a strategic partnership to cover cell and gene therapy (C>) GMP manufacturing. ABL, is a contract development and manufacturing organization (CDMO) that specializes in the development and manufacturing of solutions for biopharma, including viruses for gene therapies, oncolytic viruses and vaccine candidates. RD-Biotech is a CRO (contract research […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 24 Oct 2022 Sensorion gets go-ahead from France for trial of drug to prevent hearing loss Biotech company, Sensorion, today (October 24) announced that the initiation of a proof of concept (PoC) clinical trial of SENS-401 (Arazasetron) in patients with Cisplatin-Induced Ototoxicity (CIO) has been approved by the regulatory authorities in France. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies […] October 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 HealthTech Innovation Days brings European healthtech ecosystem together The 4th edition of HealthTech Innovation Days (HTID), organized by HealthTech For Care, took place recently in Paris, France. The two-day event had the objective of finding financing and encouraging new industrial partnerships to accelerate the development and market access of new products and treatments for all patients. Around 1,600 formal and informal face-to-face and […] October 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Domain Therapeutics to start clinical trials of solid tumor treatment Domain Therapeutics says its immuno-oncology candidate has been cleared in Belgium and France, leading to a phase I clinical trial. It has cleared its clinical trial applications with the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) […] October 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2022 Mablink Bioscience receives €31M series A funding for ADC pipeline French biotech company Mablink Bioscience has raised €31 million ($30.3 million) in series A funding to advance its lead candidate to the clinic and to build a pipeline of antibody drug conjugates (ADCs). The round was led by Sofinnova Partners and Mérieux Equity Partners. Existing shareholders Elaia Partners, UI-Investissement/Pertinence Invest 2 (advised by Mérieux Equity […] October 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 T-cell therapy platform trial begins in adults with blood cancers SMART102, a human T-lymphoid progenitor cell injection derived from cord blood using Smart Immune’s ProTcell platform, has entered clinical testing. The trial is being sponsored and led by Great Paris University Hospitals (AP-HP). Smart Immune SAS is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune […] October 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Inotrem says septic shock trial yields positive results Clinical stage biotech company Inotrem has announced results from its phase IIb ASTONISH clinical trial in septic shock patients. The results were revealed at the International Sepsis Forum in Barcelona, Spain. Study details ASTONISH was designed to show the efficacy of nangibotide in septic shock with a precision medicine approach aiming to identify patients who […] October 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Amolyt Pharma publishes hypoparathyroidism treatment results Amolyt Pharma has announced positive results from the second patient cohort in its phase 2a clinical proof of concept trial of AZP-3601, a PTH1 receptor agonist, which the company is developing as a potential treatment for hypoparathyroidism. Consistent with the findings from cohort 1, in the full data set from the phase 2a study, AZP-3601 […] October 12, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2022 The biggest private biotech investments in September 2022 The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […] October 11, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Ginkgo Bioworks acquires Altar and Circularis Ginkgo Bioworks has announced the acquisition of two biotech companies, Altar, a French firm with a proprietary adaptive evolution platform, and Circularis, which has a proprietary circular RNA and promoter screening platform. Altar acquisition A fleet of Altar’s automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo’s Foundry to serve customers across food and […] October 4, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Poxel granted orphan drug designation for kidney disease treatment French biopharma company Poxel SA says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator – and is also a phase 2 ready ADPKD asset, subject […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2022Beyond Biotech podcast 16: Adocia, Omnio, Phenomix Sciences, Tridek-One This week, we have four guests: Olivier Soula, deputy-CEO and director of R&D at Adocia; Ulrika Norin, CEO of Omnio; Mark Bagnall, CEO of Phenomix Sciences; and Laurence de Schoulepnikoff, CEO of Tridek-One. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. This week’s podcast is sponsored […] September 30, 2022 Share WhatsApp Twitter Linkedin Email